METTL3 and hepatocellular carcinoma: STM2457, a Mettl3 inhibitor, reduces Egfr's m6A modification to increase HCC cells sensitivity to lenvatinib177, and UZH1A selectively binds to Mettl3 mRNA to exert antitumor effects in leukemia and osteosarcoma178.